Startup Rana Therapeutics has named Art Krieg as its president and CEO.
Krieg was most recently an entrepreneur in residence at venture capital firm and Rana investor Atlas Venture. Before that, he served as head of Pfizer's oligonucleotide therapeutics unit.
In conjunction with the close of a Series A round of financing, Rana has also appointed two new board members: Brian Gallagher, a partner at Rana investor SR One, and Stephen Padgette, a vice president at Rana investor and ag-bio firm Monsanto.